论文部分内容阅读
There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003.Through pains-taking analyses of genomic profiles in cancer patients,a number of targetable gene alterations have been discovered,with some leading to novel therapies,such as activating mutations of EGFR,BRAF and ALK gene fusions.As a result,clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers,such as lung adenocarcinomas and melanomas.In this review,we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer(NSCLC)as an example.We also discuss possible future implications of cancer genome analyses.
There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyzes of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. in this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyzes.